SETDB1 and neoplasm: In a recent study published in Nature, Griffin et al. reported that blockade of SETDB1 enhances anti-tumor immune response, shedding new light on the potential epigenetic therapy to specifically improve immune checkpoint blockade (ICB) effectiveness.1